Abstract
Offshoring clinical trials to emerging markets around the world is receiving
increasing attention as a very attractive alternative in the clinical
development process. This follows as a natural reaction to already successful
offshoring activities in the IT industry. The big question is: Do clinical
research capabilities comparable to the US in terms of sophistication and
FDA-compliance exist anywhere else in the world? And if they do, are they
ready to handle the huge surge in business likely headed their way?
Outsourcing Clinical Trials: A Global Analytical Guide and Comparative
Analysis of International Destinations, with Location Attractiveness Index
analyzes the key drivers that have made the search for effective clinical
trial outsourcing a necessity rather than an option in today' s drug
development efforts. The current climate of clinical trials in emerging
markets across the world is examined. Geographic areas covered include
Central and Eastern Europe, Latin America, Australia and New Zealand,
Africa, Asia and India.
The report also includes the Clinical Trial Outsourcing Global
Attractiveness Index. This vital piece of original research includes
tables and graphs which rank international locations, according to the
following criteria:
- Study Cost Indicators
- Patient Indicators
- Disease Indicators
- Clinical Research Indicators
- Research Personnel Indicators
- Study Site Indicators
- Business Environment Indicators
The index serves as an invaluable starting resource for pharmaceutical
companies seeking to outsource their clinical trial functions to international
destinations.
Each region covered in this report includes the following sub-sections, which
break down, in depth, the factors vital to an understanding of international
clinical trial outsourcing destinations:
- Location
- Target Population
- Alternative Medicine
- Disease Demographics
- Study Investigator Profile
- Study Site Characteristics
- Regulatory Climate
- Study Costs
- Clinical Trial Activity
- Pharmaceutical Market
- Key Market Advantages/Strengths
- Key Market Disadvantages/Weaknesses
- Report Recommendations
Reasons to buy this report:
- Focused only on outsourcing of clinical trials - This is the primary
short-term focus of Pharma companies in developed nations. Content is not
diluted by an excessive discussion of US-based clinical trials or US-based
CROs or by too broad an analysis of overall pharma outsourcing
- Provides in depth analysis as to why particular regions are becoming
preferred destinations for Pharma outsourcing in general and clinical trials
in particular
- Provides objective comparative analysis of regions/countries and their
potential as clinical trial destinations. This analysis assesses individual
destination strengths with regard to scientific merit, technical capability,
manpower, facilities, etc.
- Prepared by an experienced team of authors who have a deep understanding
of industry dynamics and also have innumerable sources within the pharma
industry to help the reader gain the “insider” advantage
View Cart
